Multiple myeloma, secondary liver amiloidosis. Description of the clinical case


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Background. Multiple myeloma, or Rustitzky-Kahler’s disease (a plasma cell malignancy), is a disease of the hematopoietic system related to paraproteinemic leukemia. Secondary systemic amyloidosis is one of the complications of this disease. The article presents the literature data on etiology, pathophysiology, clinical manifestations, diagnosis and treatment options for this pathology. Description of the clinical case. A description of the clinical case reflecting the course of multiple myeloma complicated by secondary systemic amyloidosis is presented. Conclusion. Practitioners should pay special attention to the interpretation of data for the evaluation of liver fibrosis obtained by performing non-invasive diagnostic techniques. In the presence of results that contradict each other or significantly differ from each other, it is advisable to recommend a needle liver biopsy.

Texto integral

Acesso é fechado

Sobre autores

I. Bakulin

North-Western State Medical University n.a. I.I. Mechnikov

I. Oganezova

North-Western State Medical University n.a. I.I. Mechnikov

O. Medvedeva

North-Western State Medical University n.a. I.I. Mechnikov

V. Petrenko

North-Western State Medical University n.a. I.I. Mechnikov

Yury Medvedev

North-Western State Medical University n.a. I.I. Mechnikov

Email: medvedev.yury1990@gmail.com
Postgraduate Student at the Department of Propaedeutics of Internal Diseases, Gastroenterology and Dietology

Bibliografia

  1. http://www.dissercat.com/content/ kliniko-patofiziologicheskie-mekhanizmy-razvitiya-osteopenicheskogo-sindroma-pri-mnozhestven#ixzz55lX9OV9i (дата обращения 20.06.2018).
  2. Moreau P., San Miguel J., Sonneveld P., et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017;28(Suppl. 4):52-61. doi: 10.1093/annonc/mdx096.
  3. Palumbo A., Bringhen S., Ludwig H., et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118:4519-29. doi: 10.1182/blood-2011-06-358812.
  4. https://emedicine.medscape.com/ articie/204369-overview#a7 Updated: May 26, 2017дата обращения 1.06.2018.
  5. Rajkumar S.V., Dimopoulos M.A., Palumbo A., et al. International Myeloma Working Group updated criteria for the diagnosis of muitiple myeloma. Lancet Oncol 2014;15:e538-e548. doi: 10.1016/S1470-2045(14)70442-5.
  6. Rajkumar S.V. Updated diagnostic criteria and staging system for muitiple myeloma. Am. Soc. Ciin. Oncol. Educ. Book. 2016;35:418-23. doi: 10.14694/EDBK_159009.
  7. Terpos E., Kieber M., Engelhardt M., et al. European Myeloma Network guidelines for the management of muitipie myeloma-related complications. Haematologica. 2015;100:1254-66. doi: 10.3324/haematol.2014.117176.
  8. Клинические рекомендации по диагностике и лечению множественной миеломы / Под руководством В.Г. Савченко, И.В. Поддубной. II Конгресс гематологов России, 2014.
  9. Козловская Л.В., Рамеев В.В. Проект Клинических рекомендаций по диагностике и лечению системного амилоидоза (AA, AL). Научное общество нефрологов России, 2014 г http:// www. nonr. ru/wpcontent/uploads/2013/11. Клинические рекомендации амилоидоз.pdf -дата обращения 10.06.2018.
  10. Hansen M.T., Forst B., Cremers N., et al. A link between inflammation and metastasis: serum amyloid A1 and A3 induce metastasis, and are targets of metastasis-inducing S100A4. Oncogene. 2015;34(4):424-35. Doi: 10.1038/ onc.2013.568.
  11. Нефрология: национальное руководство / Под ред. Н.А. Мухина. М., 2009. 716 с.
  12. Desport E., Bridoux F., Sirac C., et al. AL Amyloidosis Orphanet. J. Rare Dis. 2012;7:54. doi: 10.1186/1750-1172-7-54.
  13. Lovat L.B., Persey M.R., Madhoo S., et al. The liver in systemic amyloidosis: insights from 123I serum amyloid P. component scintigraphy in 484 patients. GUT. 1998;42(5):727-34. Doi:10.1136/ gut.42.5.727.
  14. Бакулин И.Г., Медведев Ю.В. ,3С-метацетиновый дыхательный тест при оценке функционального резерва печени. Фарматека 2016;Гастроэнтерология/ Гепатология:71-80.
  15. Менделеева Л.П., Вотякова О.М., Покровская О.С. и др. Национальные клинические рекомендации по диагностике и лечению множественной миеломы. Гематология трансфузиология. 2014;1(прил. 3):1-24.
  16. Rajkumar S.V. Myeloma today: Disease definitions and treatment advances. Am. J. Hematol. 2016;91(1):90-100. doi: 10.1002/ajh.24236.
  17. Palumbo A., Rajkumar S.V. Treatment of newly diagnosed myeloma. Leukemia. 2009;23(3):449 56. doi: 10.1038/leu.2008.325
  18. Bensinger W.I. Role of autologous and allogeneic stem cell transplantation in myeloma. Leukemia. 2009;23(3):442-48.
  19. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. 2003;38(2):518-26. Doi:10.1053/ jhep.2003.50346.
  20. Бакулин И.Г., Сандлер Ю.Г. Цирроз печени: что нового в лечении? Эффективная фармакотерапия. 2014;43:42-50.
  21. Бакулин И.Г., Сандлер Ю.Г., Кейян В.А., и др. Оценка стеатоза печени с помощью неинвазивного метода: миф или реальность? Доктор.Ру. 2015;12(113):57-64.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2018

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies